Boston Scientific plea deal
This article was originally published in The Gray Sheet
Firm's Guidant subsidiary will plead guilty to two misdemeanor charges related to its failure to include information in product safety reports to FDA, Boston Scientific announces Nov. 6. The plea is part of a settlement with the Department of Justice stemming from an investigation launched in 2005 by the U.S. Attorney's Office in Minneapolis (1"The Gray Sheet" Oct. 31, 2005). The federal investigators scrutinized whether then-independent Guidant made timely disclosures to FDA regarding malfunctions of its Ventak Prizm 2, Contak Renewal and Contak Renewal 2 implantable defibrillators. The products were the subject of a series of product safety advisories in 2005 amid criticism of industry and FDA processes for disclosing, tracking and responding to adverse event data. As part of the agreement, Boston Scientific will pay $296 million. On the same day, Boston Scientific disclosed to the Securities and Exchange Commission that it received a subpoena on Sept. 25 from the Health and Human Services Office of Inspector General requesting information relating to contributions made by the company's cardiac rhythm management division "to charities with ties to physicians or their families." The firm says it is "working with the government to understand the scope of the subpoena.
You may also be interested in...
Boston Scientific's hopes of putting one significant source of Guidant-inherited legal troubles behind it hit at least a short delay last week
The Department of Justice is increasingly tackling issues of FDA compliance beyond the standard sales and marketing fare, pursuing cases related to device manufacturing, adverse event reporting and even product labeling, recent cases suggest
Subpoenas served to Guidant, Medtronic and St. Jude Medical by the U.S. Department of Justice appear to be investigating potential improper inducements to increase sales of pacemakers and ICDs